Physician profile
Monique A Gary
NPI 1861622532
$106,694.33
in general payments reported to CMS, 2019-2025
21 companies · $28K in 2025
The $28K reported for 2025 was more than what 98% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,577 · 2020: $198 · 2021: $9,743 · 2022: $44K · 2023: $16K · 2024: $4,643 · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $34K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Travel and Lodging: $1,667 · Food and Beverage: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $33,858.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,917.50 |
| Travel and Lodging | $1,667.23 |
| Food and Beverage | $450.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $33,395.64 | 2022-2025 | Kisqali |
| Stryker Corporation | $28,920.46 | 2019-2023 | Spy-Phi System |
| Merck Sharp & Dohme LLC | $17,633.64 | 2021-2025 | Keytruda, Lynparza |
| Lilly USA, LLC | $10,442.26 | 2024-2025 | Verzenio |
| Astrazeneca Pharmaceuticals LP | $6,444.00 | 2021-2025 | |
| Pfizer INC. | $4,512.50 | 2023-2024 | |
| Daiichi Sankyo INC. | $3,000.00 | 2022 | |
| Myriad Genetic Laboratories, INC. | $733.51 | 2021-2023 | Myrisk |
| Carl Zeiss Meditec USA, INC. | $542.76 | 2022-2023 | Intrabeam |
| Gilead Sciences, INC. | $364.07 | 2021-2023 | |
| Elucent Medical | $245.45 | 2019 | |
| Janssen Pharmaceuticals, INC | $159.16 | 2020-2021 | |
| Focal Therapeutics, INC. | $68.40 | 2020 | |
| Dilon Technologies, INC. | $56.83 | 2021 | |
| Tela Bio, INC. | $37.34 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innocoll Pharmaceuticals Limited | $34.48 | 2021-2022 | |
| Ethicon US, LLC | $27.05 | 2019 | |
| Davol INC. | $26.44 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $20.64 | 2019 | |
| Intuitive Surgical, INC. | $18.28 | 2019 | |
| Smith+Nephew, INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monique Gary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.